Antibodies induced by mRNA COVID-19 vaccines keep improving in quality for at least six months while the immune system continues to “train” its antibody-producing B cells, according to a new study. In other research, dysfunctional red blood cells contribute to the blood vessel injuries common in severe COVID-19, according to laboratory studies that also may suggest a way to treat the problem.
Because the Omicron variant of COVID-19 is so infectious, it is surging around the United States. Vaccination is still the best way to prevent severe disease and death, but there is increasing debate on the benefit of yet another booster shot and how long people who show symptoms should quarantine.
The risk of hospitalization with the Omicron variant of coronavirus is about one-third that of the Delta variant, according to British analysis of more than a million cases of both types in recent weeks.
Cyrus Biotechnology announced that the Seattle-based biotechnology firm’s pre-clinical stage COVID therapeutic lead molecule, ACE2.v2.4 strongly binds the spike protein of SARS-CoV-2 variant of concern (VOC) omicron.
Healthcare disruptions linked to the coronavirus pandemic helped malaria kill 69,000 more people in 2020 than the previous year, but a worst-case scenario was averted, the World Health Organization said on December 6.
Researchers with the University of Cambridge for the first time leveraged human data to quantify the speed of various processes in the brain that lead to Alzheimer’s disease.
British scientists identified a version of a gene that may be associated with double the risk of lung failure from Covid-19, a finding that provides new insights into why some people are more susceptible than others to severe illness and which opens possibilities for targeted medicine.
The White House said on Nov. 4 that understanding the origins of Covid-19 remains a key focus of the Biden administration and that they will continue pushing for answers.
Europe registered a 55 percent rise in Covid-19 cases in the last four weeks, despite the availability of vaccines, which should serve as a “warning shot” to other regions, World Health Organization (WHO) officials said on November 4.
Durham, North Carolina-based Ribometrix announced a strategic collaboration deal with Roche company Genentech to identify and advance novel RNA-targeted small molecule therapeutics.